Research programme: reduced gastric irritation NSAIDs - Oxford Pharmascience

Drug Profile

Research programme: reduced gastric irritation NSAIDs - Oxford Pharmascience

Alternative Names: OXP 006; OXP 007; OXPzero™ Aspirin

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford Pharmascience
  • Class Nonsteroidal anti-inflammatories; Phenylacetates; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Musculoskeletal pain
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 27 Sep 2017 Suspended for Musculoskeletal pain in United Kingdom, pending conclusion of a strategic review (PO)
  • 09 Nov 2016 Discontinued for OXPzero™ aspirin programme for Cardiovascular disorders in United Kingdom (PO)
  • 02 Jul 2015 Early research in Cardiovascular disorders in United Kingdom (PO) prior to July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top